Immunovant (IMVT) Current Assets (2018 - 2026)

Immunovant (IMVT) has 9 years of Current Assets data on file, last reported at $948.8 million in Q1 2026.

• Quarterly Current Assets rose 23.6% year-over-year to $948.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $948.8 million (up 23.6% YoY) and the FY2026 annual result came in at $948.8 million, up 23.6% from the prior year.
• Current Assets eased to $948.8 million in Q1 2026, from $1.0 billion in the prior quarter.
• In the past five years, Current Assets ranged from a high of $1.0 billion in Q4 2025 to a low of $291.2 million in Q3 2023.
• A 5-year average of $574.4 million and a median of $512.9 million in 2022 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2024 — Current Assets plunged 41.96% — and 2025, when it jumped 152.81%.
• Tracing IMVT's Current Assets over 5 years: stood at $454.4 million in 2022, then surged by 56.41% to $710.8 million in 2023, then sank by 41.96% to $412.5 million in 2024, then jumped by 152.81% to $1.0 billion in 2025, then dropped by 9.02% to $948.8 million in 2026.
• The last three Current Assets figures came in at $948.8 million (Q1 2026), $1.0 billion (Q4 2025), and $573.5 million (Q3 2025), per Business Quant data.